Lakes Research | Miami Lakes, FL

Research site

(Unclaimed)

Location

5801 NW 151 Street, Suite 302, Miami Lakes, Florida, United States of America

Site insights

Top conditions

Top treatments

Pegcetacoplan

Pegfilgrastim

Docetaxel

Abemaciclib

Fasudil

Cyclophosphamide

APL-2

Baricitinib

Azacitidine

LY3009104

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 35 total trials

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women wit...

Active, not recruiting

Breast Cancer

Drug: Abemaciclib

Drug: Anastrozole

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to...

Enrolling

Chemotherapy-induced Nausea and Vomiting

Drug: Palonosetron HCl Buccal Film 0.5 mg

Drug: IV Palonosetron 0.25 mg

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia (ENERGY)

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Enrolling

Warm Autoimmune Hemolytic Anemia

Drug: M281

Drug: Placebo

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

This study is an open-label, single arm, multicenter, roll-over extension study to characterize long-term safety, tolerability and efficacy of iptaco...

Enrolling

Paroxysmal Nocturnal Hemoglobinuria

Drug: Iptacopan

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Enrolling

Amyotrophic Lateral Sclerosis

Drug: Fasudil (WP-0512)

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak300)

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated...

Active, not recruiting

Colorectal Cancer (CRC)

Drug: Regorafenib

Drug: Panitumumab

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg